Protocol Ledger

NCT05635162 · Phase II · RECRUITING

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Interventional Phase II clinical trial protocol NCT05635162 sponsored by University College, London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-17 Enrollment: 50 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05635162
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05635162
Protocol FieldVerified Registry Value
NCT IdentifierNCT05635162
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment50 participants (ESTIMATED)
Registered Start Date2024-05-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05635162
Hospital Research SiteLocationSite Profile
Beatson West of Scotland Cancer CentreGlasgow, United KingdomOpen Hospital Dossier ->
Guy's HospitalLondon, United KingdomOpen Hospital Dossier ->
St Bartholomew's HospitalLondon, United KingdomOpen Hospital Dossier ->
University College London HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI